Scopia Capital Management

Scopia Capital Management is an institutional alternative asset management firm that focuses on a fundamentals-based, value-driven investment approach. The company offers a diverse range of fund products that span various equity strategies, including long-short equity strategies managed with market neutrality and net long exposure, as well as a long-only equity strategy. Through its disciplined investment methodology, Scopia Capital aims to deliver value to its clients by leveraging thorough analysis and market insights in its investment decisions.

Matthew Sirovich

Founder and Managing Partner

4 past transactions

PM Pediatric Care

Series E in 2023
PM Pediatric Care is an urgent care provider dedicated to delivering specialized healthcare services for children and young adults. Founded on the principle of enhancing the quality of urgent care, the company focuses on ensuring timely access to medical treatment for various conditions, including earaches, fevers, infections, and more serious issues like fractures and asthma. PM Pediatric Care emphasizes shorter wait times and year-round availability, aiming to minimize discomfort and avoid unnecessary testing for its patients. The organization is committed to providing a high standard of care, comfort, and convenience to patients and their families during urgent medical situations.

Y-mAbs Therapeutics

Private Equity Round in 2017
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative antibody-based therapies for cancer treatment in the United States. The company's lead product, DANYELZA, is an FDA-approved monoclonal antibody targeting ganglioside GD2, which is present in various neuroectoderm-derived tumors and sarcomas. Y-mAbs is advancing several other candidates, including naxitamab, currently in Phase 2 trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, and omburtamab, also in Phase 2 trials for desmoplastic small round cell tumors. Additionally, the company is developing a GD2-GD3 vaccine and exploring the huB7-H3 candidate for adult solid tumors. Y-mAbs collaborates with leading institutions, including Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, to enhance its antibody constructs using advanced therapeutic platforms. Founded in 2015 and headquartered in New York, Y-mAbs aims to provide novel treatments that may reduce the long-term toxicities associated with traditional chemotherapies while potentially offering curative options for patients with widespread disease.

PM Pediatric Care

Venture Round in 2014
PM Pediatric Care is an urgent care provider dedicated to delivering specialized healthcare services for children and young adults. Founded on the principle of enhancing the quality of urgent care, the company focuses on ensuring timely access to medical treatment for various conditions, including earaches, fevers, infections, and more serious issues like fractures and asthma. PM Pediatric Care emphasizes shorter wait times and year-round availability, aiming to minimize discomfort and avoid unnecessary testing for its patients. The organization is committed to providing a high standard of care, comfort, and convenience to patients and their families during urgent medical situations.

Zalora

Venture Round in 2013
Zalora is an e-commerce company specializing in fashion and footwear. It operates an online platform offering a wide range of products from various international fashion labels, including Mango, Nike, and Levi's. Customers can browse and purchase items, with options for cash-on-delivery and free returns within 30 days. Zalora is known for its efficient logistics, providing speedy and reliable deliveries. It also offers fashion tips, an online magazine, and discounts. Based in Vietnam, Zalora serves multiple countries and was launched in 2012.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.